With ongoing questions about the manufacturing of heparin in China and concerns about a potential shortage of the anticoagulant, some are wondering whether there is a need for new heparin alternatives. Dr. Ted Love, chief executive officer of the San Francisco biotech company Nuvelo, tells host Bruce Japsen about the biotech industry's pursuit of synthetic variations of the popular blood thinner.